

AHCL/SE/14/2017-18

May 16, 2017

he National Stock Exchange of India imited Exchange Plaza", C-1, Block G andra-Kurla Complex, Bandra (E) umbai 400 051 IN: INE098F01023	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001				
Symbol: AMRUTANJAN	Scrip Code: 590006				

Dear Sir / Madam,

Sub: Outcome of the Board Meeting - Regulation 33 read with Clause 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR)

Pursuant to the above regulation(s), we wish to inform that the Board of Directors of the Company at its meeting held today (May 16, 2017) had inter-alia:

- a. Approved the Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31st, 2017, as recommended by the audit committee at its meeting held today (May 16, 2017). The same along with the Report issued by M/s. P.S. Subramania Iyer & Co , Chartered Accountants; Statutory Auditors is enclosed;
- b. Recommended Final Dividend of Rs. 1.65 per equity share of Rs. 2 each for the financial year 2016- 2017 in addition to interim dividends of Rs. 2.20 per equity share (2 interim dividends of Rs. 1.10 each per equity share) declared and paid during the financial year 2016-17. The total dividend payout for 2016-17 is 192.50% (Rs. 3.85 per equity share of Rs. 2 each-same as that of last year). The said dividend, if declared at the Annual General Meeting, will be paid to the shareholders within 30 days of Annual General Meeting.

The Board Meeting commenced at 11.30 A.M. and concluded at 15.30 P.M

Thanking you,

Yours faithfully,

For Amrutanjan Health Care Limited

(M Srinivasan)

CHENNAI 600 004

Company Secretary & Compliance Officer

Encl:

- 1. Audited Standalone and Consolidated Financial Results for the Quarter and Year ended 31st March, 2017
- 2. Statutory Auditors Report for the period ended 31st March, 2017
- 3. Declaration on Auditors' Report with Unmodified Opinion under Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015

Amrutanjan Health Care Limited

103. (Old No. 42-45), Luz Church Road, Mylapore, Chennai - 600 004 Tamil Nadu, India.

Tel: +91-44-24994465 / 4165 / 4164 / 4366

Fax:+91-44-24994585

E-mail: customercare@amrutanjan.com Web Site: www. amrutanjan.com Toll Free No.: 1 - 800 - 425 - 4545 CIN - L24231TN1936PLC000017

AMRUTANJAN HEALTH CARE LIMITED

REGD. OFFICE: NEW NO.103 (OLD NO. 1'-45), LUZ CHURCH ROAD, MYLAPORE, CHENNAI-600 004. email id: investors@amrutanjan.com; website: www.amrutanjan.com; CIN No: L24231TN1936PLC000017 STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR YEAR ENDED 31ST MAR 2017

				STANDALONE			CONSOLIDATED	
SI No.	PARTICULARS	QUARTER ENDED			YEAR NEDED		YEAR ENDED	YEAR ENDED
		31-Mar-17	31-Dec-16	31-Mar-16	31-Mar-17	31-Mar-16	31-Mar-17	31-Mar-16
		(Audited)	(unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
	PART - I							
	Gross Sales	7,138.58	6,182.54	5,903.27	22,694.40	19,192.25	23,170.34	19,451.77
	Less : Excise Duty	261.57	313.34	266.82	1,030.29	882.33	1,060.63	905.14
1.	(a) Net Sales / Income from operations	6,877.01	5,869.20	5,636.45	21,664.11	18,309.92	22,109.71	18,546.63
	(b) Other Operating Income	90.66	71.36	32.43	288.49	127.76	288.49	127.76
	Total Income	6,967.67	5,940.56	5,668.88	21,952.60	18,437.68	22,398.20	18,674.39
2.	Expenditure							
a.	(Increase) / Decrease in Stock in Trade and work in progress	172.63	20.02	148.58	(231.98)	33.67	(193.05)	58.04
b.	Consumption of raw & other materials	1,998.93	1,682.55	1,798.05	6,991.78	5,858.90	7,283.06	6,022.94
c.	Purchase of Traded goods	822.42	238.78	202.72	1,568.42	626.80	1,568.42	626.80
d.	Employee Cost	784.50	975.87	686.36	3,306.59	2,801.22	3,358.32	2,854.68
e.	Advertisement & Selling Expenditure	1,271.18	1,295.51	882.15	3,738.28	2,967.19	3,738.28	2,967.19
f.	Depreciation	47.75	34.60	71.05	204.78	252.46	286.76	334.68
g.	Other Expenditure	1,351.57	802.27	1,077.07	3,635.43	2,987.89	3,741.27	3,078.30
8	Total Expenditure	6,448.98	5,049.60	4,865.98	19,213.30	15,528.13	19,783.06	15,942.63
3.	Profit from Operations before Other Income, Interest and Exceptional Items (1 - 2)	518.69	890.96	802.90	2,739.30	2,909.55	2,615.14	2,731.76
4.	Other Income	242.18	101.07	150.85	513.91	554.80	483.06	567.95
5.	Profit before Interest and Exceptional Items (3 + 4)	760.87	992.03	953.75	3,253.21	3,464.35	3,098.20	3,299.71
6.	Interest	3.55	0.17	1.79	12.38	8.16	43.00	31.38
7.	Profit after Interest but before Exceptional Items (5 - 6)	757.32	991.86	951.96	3,240.83	3,456.19	3,055.20	3,268.33
8.	Exceptional items	32.75	236.39		269.14		269.14	12
9.	Profit from Ordinary Activities before Tax (7 + 8)	790.07	1,228.25	951.96	3,509.97	3,456.19	3,324.34	3,268.33
10.	Tax Expense incl Deferred Tax	475.36	263.33	481.41	1,225.19	1,214.41	1,210.08	1,210.78
11.	Net Profit from Ordinary Activities after Tax (9 - 10)	314.71	964.92	470.55	2,284.78	2,241.78	2,114.26	2,057.55
12.	Extraordinary Items :	-		400	-	- 2		(H)
13.	Net Profit for the Period (11 + 12)	314.71	964.92	470.55	2,284.78	2,241.78	2,114.26	2,057.55
14.	Paid-up Equity Share Capital (Face Value Rs.2 /- (Rs. 2/- each)	292.31	292.31	292.31	292.31	292.31	292.31	292.31
15.	Reserve excluding Revaluation Reserves as per Balance Sheet of previous accounting year		-			11,755.46		10,581.79
16.	Earnings Per Share EPS - Rs. (Not Annualised)						FREE PART	
	a) Basic and diluted EPS before Extraordinary items (Rs.)	2.15	6.60	3.22	15.63	15.34	14.47	14.08
	b) Basic and diluted EPS after Extraordinary items (Rs.)	2.15	6.60	3.22	15.63	15.34	14.47	14.08

Notes:

- 2 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 16th May 2017.
- The figures for the previous quarter / period have been regrouped / reclassified whereever necessary.

Chairman & Managing Director

Place : Chennai Date : 16th May 2017

Page 1 of 2

AMRUTANJAN HEALTH CARE LIMITED

REGD. OFFICE: NEW NO.103 (OLD NO. 42-45), LUZ CHURCH ROAD, MYLAPORE, CHENNAI - 600 004.

email id: investors@amrutanjan.com; website: www.amrutanjan.com; CIN No: L24231TN1936PLC000017

STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR YEAR ENDED 31ST MAR 2017

Segmentwise Revenue, Results and Capital Employed under Clause 41 of the Listing Agreement

		nder Clause 41 o	STANDALONE	Joinone		CONSOLI	DATED	
PARTICULARS	QUARTER ENDED			YEAR E	NDED	YEAR ENDED		
	31-Mar-17	31-Dec-16	31-Mar-17	31-Mar-17	31-Mar-16	31-Mar-17	31-Mar-16	
	(Audited)	(unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	
1 Segment Revenue								
		- 1			1			
Net Sales				40.000.00	10 100 50	40 702 70	16,138.50	
a) O T C Products	5,518.33	5,571.30	4,739.12	18,793.76	16,138.50	18,793.76	236.71	
b)Chemicals	-	-	-		0.474.40	445.60 2,949.94	2,171.42	
c) Beverages	1,367.96	312.68	897.33	2,949.94	2,171.42		127.76	
d) APMC	81.38	56.58	32.43	208.90	127.76	208.90	18,674.39	
Total	6,967.67	5,940.56	5,668.88	21,952.60	18,437.68	22,398.20	10,074.39	
Less: Inter segment revenue	-	-	5 000 00	04.050.00	40 407 00	22 200 20	10 674 20	
Sales / Income from operations	6,967.67	5,940.56	5,668.88	21,952.60	18,437.68	22,398.20	18,674.39	
2 Segment Results Profit/(Loss) Before Tax and Interest								
a) O T C Products	604.68	1,016.71	952.22	3,299.79	3,542.32	3,299.79	3,542.32	
b)Chemicals	-	-			-	(146.19)	(178.50)	
c) Beverages	31.37	(109.20)	(75.39)	(320.90)	(245.74)	(320.90)	(245.74)	
d) APMC	1.37	(19.95)	(32.22)	(107.99)	(165.55)	(107.99)	(165.55)	
Total	637.42	887.56	844.61	2,870.90	3,131.03	2,724.71	2,952.53	
Less : i) Interest	3.55	0.17	1.79	12.38	8.16	12.38	8.16	
ii) Other un-allocable expenditure		4	1					
net off unallocable income	(123.45)	(104.47)	(109.14)	(382.31)	(333.32)	(342.87)	(323.96	
Less: Exceptional items	(32.75)	(236.39)		(269.14)	-	(269.14)	(2)	
Add: Extraordinary Items			-	•	-		(*)	
Total Profit Before Tax	790.07	1,228.25	951.96	3,509.97	3,456.19	3,324.34	3,268.33	
3 Segment Assets			AND REAL PROPERTY.				96.00.40.50.00.00.00	
a) O T C Products	10,427.52	10,211.86	8,358.16	10,427.52	8,358.16	10,427.52	8,358.16	
b)Chemicals	-117		-			1,231.53	1,146.36	
c) Beverages	1,910.33	1,864.92	1,357.39	1,910.33	1,357.39	1,910.33	1,357.39	
d) APMC	32.14	32.72	35.90	32.14	35.90	32.14	35.90	
e) Unallocated	4,819.46	4,680.82	5,122.08	4,819.46	5,122.08	2,574.52	3,146.02	
Total	17,189.45	16,790.32	14,873.53	17,189.45	14,873.53	16,176.04	14,043.83	
4 Segment Liabilities					1			
a) O T C Products	2,479.82	2,419.49	1,949.10	2,479.82	1,949.10	2,479.82	1,949.10	
hiChamicala				-	-	330.78	343.97	
b)Chemicals	730.00	509.51	541.20	730.00	541.20	730.00	541.20	
c) Beverages	730.00	303.31	541.20					
d) APMC	34.07	36.97	335,46	34.07	335.46	34.07	335.46	
e) Unallocated Total Capital Employed in company	3,243.89	2,965.97	2,825.76	3,243.89	2,825.76	3,574.67	3,169.73	

1.STATEMENT OF ASSETS AND LIABILITIES

	STANDA	STANDALONE		
PARTICULARS	YEAR E	YEAR ENDED		
	31-Mar-17	31-Mar-16	31-Mar-17	31-Mar-16
A) EQUITY AND LIABILITIES				
Shareholders' funds				
a)Shareholders funds	292.31	292.31	292,31	292.31
b)Reserve and surplus	13,653.25	11,755.47	12,309.06	10,581.79
Sub-total - Shareholders funds	13,945.56	12,047.78	12,601.37	10,874.10
2) Non-Current liabilities				
a) Long-term borrowings	• 1500	-		0.00
b) Deferred tax liabilities (net)	202.40	191.39	253.01	257.11
c) Other Long-term Liabilities	46.94	41.98	46.94	41.98
d) Long-term Provisions	73.03	73.03	73.03	73.03
Sub-total - Non-Current liabilities	322.37	306.40	372.98	372.12
3) Current liabilities				
a) Short-term borrowings		-	248.28	250.00
b) Trade payables	1,372.18	907.21	1,395.24	927.56
c) Other current Liabilities	1,515.27	1,429.83	1,524.10	1,437.73
d) Short-term provisions	34.07	182.33	34.07	182.33
Sub-total - Current liabilities	2,921.52	2,519.37	3,201.69	2,797.62
TOTAL - EQUITY AND LIABILITIES	17,189.45	14,873.55	16,176.04	14,043.84
B) ASSETS				
Non-current Assets				
a) Fixed assets	2,530.95	2,321.62	3,087.94	2,963.07
b) Non-current investments	978.89	982.42	897.79	898.84
c) Long-term loans and advances	2,163.84	1,971.06		-
d) Other non-current assets	188.67	132.62	1,113.67	132.62
Sub-total - Non-current Assets	5,862.35	5,407.72	5,099.40	3,994.53
Current assets				
a) Current investments				-
b) Inventories	980.26	790.78	1,002.57	897.35
c) Trade receivables	3,309.92	2,617.75	3,633.66	2,758.68
d) Cash and cash equivalents	4,720.36	4,795.31	4,744.92	4,824.45
e) Short-term loans and advances	1,944.01	899.68	1,322.94	1,206.52
f) Other Current assets	372.55	362.31	372.55	362.31
Sub-total - Current Assets	11,327.10	9,465.83	11,076.64	10,049,31
TOTAL ASSETS	17,189.45	14,873.55	16,176.04	14,043.84

Chairman & Managing Director

S. Sambhu Prasad

Place : Chennai

Date : 16th May 2017



P. S. SUBRAMANIA IYER & CO.

CHARTERED ACCOUNTANTS

New No. 103, (Old No. 57/2), P. S. Sivasamy Salai, (Sullivan Garden Road), Mylapore, Chennai - 600 004. Phone: 2499 2449 / 2499 2470

E-mail: pssco 2000@yahoo.com pssandco@gmail.com

Auditor's Report On Quarterly Financial Results and Year to Date Results of Amrutanjan Health

Care Limited, Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 2015.

To

Board of Directors of

Amrutanjan Health Care Limited,

Chennai

We have audited the quarterly financial results of **Amrutanjan Health Care Limited** for the quarter ended March 31, 2017 and the year to date results for the period from April 1, 2016 to March 31, 2017. attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements)Regulations,2015. These quarterly financial statements, results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been proposed in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25), prescribed, under Section 133 of the Companies Act,2013 read with relevant rules issued there under and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

(Our Bank Details : State Bank of Mysore, Branch Abhiramapuram, Current A/c. No. 54008541474 IFS Code : SBMY0040203 - HDFC Bank, Branch R.A. Puram, Current A/c. No. 01412000002912

IFSC Code: HDFC0000141 - Service Tax Regn. No. AAAFP3234H ST001 - PAN: AAAFP3234 H)

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regualtion33 of the SEBI (Listing Obligations and Disclosure Requirements)Regualtions,2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2017 as well as the year to date results for the period from April 1, 2016 to March 31, 2017.

For P.S.Subramania Iyer &Co Chartered Accountants Firm Registation No.004104S

New No. 103, Old No. 57/2, P.S. Sivasamy Road Milapore, Channai-600 004

V.Swaminathan
Partner
M.No:022276

Place of signature: Chennai

Date: 16/05/2017.



P. S. SUBRAMANIA IYER & CO.

CHARTERED ACCOUNTANTS

New No. 103, (Old No. 57/2), P. S. Sivasamy Salai, (Sullivan Garden Road), Mylapore, Chennai - 600 004. Phone: 2499 2449 / 2499 2470

E-mail: pssco_2000@yahoo.com pssandco@gmail.com

Auditor's Report On Quarterly Consolidated Financial Results and Consolidated Year to Date Results of Amrutanjan Health Care Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To

Board of Directors of

Amrutanjan Health Care Limited,

Chennai

We have audited the quarterly consolidated financial results of **Amrutanjan Health Care Limited** for the quarter ended March 31, 2017 and the consolidated year to date results for the period April 1, 2016 to March 31, 2017 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 o f the SEBI(Listing Obligations and Disclosure Requirements), Regualtions, 2015. These consolidated quarterly financial results as well as the consolidated year to date financial results have been prepared from consolidated interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles' laid down in Accounting Standard for Interim Financial Reporting AS 25, mandated under Section 133 of the Companies Act, 2013 read with relevant rules issued there under as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the Auditing Standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these consolidated quarterly financial results as well as the consolidated year to date results:

(Our Bank Details: State Bank of Mysore, Branch Abhiramapuram, Current A/c. No. 54008541474) IFS Code: SBMY0040203 - HDFC Bank, Branch R.A. Puram, Current A/c. No. 01412000002912 IFSC Code: HDFC0000141 - Service Tax Regn. No. AAAFP3234H ST001 - PAN: AAAFP3234 H)

(i) Include the quarterly financial results and year to date of the following entities:
 Amrutanjan Pharmaessense Private Limited

(ii) Have been presented in accordance with the requirements of regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations,2015 in this regard; and

(iii) give a true and fair view of the consolidated net profit and other financial information for the quarter ended 31 March, 2017 a s well as the consolidated year to date results for the period from 1 April 2016 to 31 March, 2017.

For P.S.Subramania Iyer &Co Chartered Accountants Firm Registration No.004104S

New No. 103, Old Nn. 5712, P.S. Sivas amy Road Mylapote, Chennal-800 004

V.Swaminathan Partner M.No:022276

Place of signature: Chennai

Date: 16/05/2017



May 16, 2017

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01023	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001
Symbol : AMRUTANJAN	Scrip Code: 590006

Dear Sir/ Madam,

Sub: Declaration on Auditors' Report with unmodified opinion under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We, Mr. S Sambhu Prasad, Chairman and Managing Director and Mr. K Kannan, Chief Financial Officer of Amrutanjan Health Care Limited (CIN: L24231TN1936PLC000017) hereby declare that in terms of the provisions of the above said regulations as amended by SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016 vide notification no. SEBI/LAD- NRO/GN/2016-17/001 dated May 25, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016, the Statutory Auditors of the Company, M/s. P S Subramania Iyer & Co., Chartered Accountants (Firm Registration no. 004104S) having issued an Audit Report with unmodified opinion on the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2017.

Kindly request to take this declaration on record.

Thanking You

Yours faithfully

For Amrutanjan Health Care Limited

(S Sambhu Prasad) 600 004

Chairman and Managing Director

(K Kannan)

Chief Financial Officer

Highlights of YTD Mar 2017 and Q4 results

YTD Mar 2017

- > Gross sales of the Company have increased from Rs. 192 cr. to Rs. 230 Cr. (19.3 % Growth)
- > Profit Before Tax is Rs. 35.09 Cr. against Rs. 34.56 Cr. of previous year
- > Profit after Tax is Rs. 22.84 Cr against Rs. 22.41 Cr. of previous year
- Earnings per share has gone up from 15.34 for 2015-16 to 15.63 for 2016-17

OTC Division

- Gross sales of OTC have increased from Rs. 170 cr. To Rs. 198 Cr. (16.5 % Growth out of which volume growth is 14 %)
- Sanitary Napkin -- COMFY sales has grown from Rs. 2.95 Cr (2015-16) to Rs. 8.30 Cr. (2016-17)
- > The price increase in Raw materials like Nilgiri ka Tel and Pudhina Ka phool the increase in packing material cost in Q4 have resulted in dip in margins.
- > Investment in additional manpower cost and in Advertisement activities have impacted the bottom line.

Fruitnik Division

- ➢ Gross Sales have increased from Rs. 22 Cr. of 2015-16 to Rs. 29 Cr. for 2016-17.
- > The New Product ORS has been launched and a turnover of Rs. 3130 Cr. have been achieved
- > The product ORS is contributing positive margins.

Q4 Performance

- > Gross Sales of OTC increased from Rs. 49.93 Cr. to Rs. 57.67 Cr. for Q4 (16 % increase over last year same period)
- Gross Sales of F & B divn. increased from Rs. 9.15 Cr. to Rs. 13.82 Cr. for YTD Dec (51 % increase over last year same period)
- Revenue in Pain management Centre for Q4 is Rs. 81.38 lakhs as against Rs. 32.43 Lakhs during Q4 of 2015-16.